NanoViricides Signs Agreement for Ocular Testing of Its Drug Candidates for the Treatment of Herpes Keratitis with the University of Pittsburgh
PR Newswire

SHELTON, Conn., Feb. 11, 2016 /PRNewswire/ -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company") announced today that it has entered into an agreement with the University of Pittsburgh for the testing of its nanoviricides® drug candidates in standard animal models of ocular virus infections.

Targeted Virus-Killing Nanomedicines (PRNewsFoto/)

The research will be performed in the Charles T. Campbell Ophthalmic Microbiology Laboratory by Dr. Eric Romanowski, Research Director. Dr. Romanowski has extensive experience in ocular virus infections and anti-viral agents discovery.

These animal studies will evaluate the efficacy and potency of the Company's nanoviricides anti-viral agents in ocular viral infections. The goal of these studies is to help select clinical drug development candidates for treatment of ocular herpes keratitis in humans.

"We are very pleased to have the Campbell Laboratory join our efforts in developing a drug against Herpes Keratitis," said Eugene Seymour, MD, MPH, CEO of the Company, adding, "This is a renowned lab in the field of ocular infections with substantial experience in antiviral drugs development. We plan to perform IND-enabling efficacy studies of our anti-viral agents at the Campbell Labs."

The Charles T. Campbell Ophthalmic Microbiology Laboratory is part of the University of Pittsburgh Medical Center's Eye Center (UPMC Eye Center).  The UPMC Eye Center in the Department of Ophthalmology of the University of Pittsburgh School of Medicine has one of the top basic and clinical research programs in the country. UPMC Eye Center's research focuses on infectious disease, ocular immunology, molecular genetics and molecular biology of retinal disease, glaucoma and advanced diagnostic imaging technology development.

About NanoViricides: 
NanoViricides, Inc. ( is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities.  Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

Logo -

To view the original version on PR Newswire, visit:

SOURCE NanoViricides, Inc.

 Top of page